Adverse Event Management

Oncology nurses can help optimize quality of life in patients by addressing interrelated symptom clusters.

Oncology nurses can aid in the identification and management of oral adverse effects from cancer therapies.

A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.

The implementation of a nurse navigator in a lymphedema program has helped patients with the condition obtain timely care, which can potentially improve outcomes.

From journaling to delegating everyday tasks, nurses can teach patients how to cope with treatment-related fatigue.

A pilot study proved that a nurse-coordinated approach shows promise in treating more than just 1 symptom among patients with cancer.

A subgroup of patients from the 3 CARTITUDE trials experienced cranial nerve palsy after treatment, most of whom were men.

Patients who were given telehealth, vs in-person, exercise programs to manage their symptoms from cancer care experienced similar outcomes, highlighting an alternative for providers to consider.

Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.

Older patients with cancer demonstrated a moderate to high symptom burden, leading to the need for routine symptom assessments and tailored management interventions.

An expert discussed a screening tool that she and her colleagues used to connect patients with cancer to palliative care services in a more effective way.

Zanubrutinib to treat chronic lymphocytic leukemia or small lymphocytic lymphoma was linked with fewer cardiac adverse effects compared with ibrutinib and acalabrutinib.

Oncology nurses provide patients with lung cancer the education and empathy needed to navigate treatment options and adverse event management.

Virtual reality headsets can be used to reduce anxiety in patients with cancer undergoing treatment and as an educational tool for nurses learning how to have difficult conversations with patients.

Bispecific antibodies that engage T cells are an effective treatment modality in relapsed/refractory disease and are an important new treatment for relapsed large B-cell lymphoma.

Difficult conversations in cancer pain management should include core values and principles, setting realistic expectations, and building the patient-client relationship from the very beginning.

A recent study found that a 2.5-mg dose of olanzapine was noninferior to the 10.0-mg dose to control nausea/vomiting in patients with solid tumors treated with chemotherapy and was able to reduce daytime drowsiness from the drug.

Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.

With pembrolizumab plus chemoradiotherapy now approved by the FDA for patients with advanced cervical cancer, one expert explained the importance of “making sure that patients know what to look for and what to report.”

Treatment with regorafenib in patients with unresectable hepatocellular carcinoma and poor liver function may lead to serious side effects that may result in discontinuation of the treatment.

A modified dosing schedule may make treatment with ipilimumab plus nivolumab more tolerable for patients with advanced renal cell carcinoma.

Kizzie Charles, MS, APRN, AGCNS-BC, CNOR, walks through the process of developing a successful quality improvement project in the perioperative oncology setting.

New targeted therapies offer certain patients with non–small cell lung cancer more second-line treatment options.

Leah Shaw, MSN, APRN, AGPCNP-BC; and Jessica Deinert, MSN, APRN, FNP-BC, share their clinical pearls in managing treatment-related adverse events in prostate cancer care.

The increasing use of biosimilars makes prophylaxis with growth factor more cost effective.

Electronic patient-reported outcomes may have a place in high-quality cancer care, according to investigators.

Nurses can be empowered to advocate for methylene blue therapy as an effective oral mucositis pain relief treatment.

Data from a single-institution study showed that 98.6% of their patients with head and neck cancer experienced oral mucositis.

Melanie Taylor, APRN, and Mark Lin, APRN, share how they optimize strategies in caring for patients with lymphedema.

Steroids are the standard approach in immune-related adverse events; however, some experts maintain that other management strategies are needed.